调研中，李强主持召开座谈会。听取有关企业和投资、研发、医疗机构负责人发言后，李强指出，生物 医药产业既是战略性新兴产业，也事关人民健康福祉。要加强原始创新和关键核心技术攻关，发挥政府 和市场两方面作用，充分调动各类资源，凝聚创新合力，尽快取得更大突破。要注重运用人工智能全面 赋能产业发展，提高药物研发、临床试验、诊断治疗、生产流通等环节智能化水平。要强化产品研发、 审评审批、管理使用等政策衔接和协同配合，优化药品集采和谈判议价机制，加大高水平创新药应用指 导力度。李强强调，要依靠创新促进中医药振兴发展，充分运用现代科学的理论、技术、材料等，深化 中医药基础理论、诊疗规律、作用机理的研究阐释，丰富治疗方法，推进中医药现代化、产业化。 原标题：李强在北京调研生物医药产业发展时强调加大高质量科技供给和政策支持着力推动生物医药产 业提质升级 新华社北京8月20日电中共中央政治局常委、国务院总理李强8月20日在北京调研生物医药产业发展情 况。他强调，要深入贯彻习近平总书记关于生物医药产业发展的重要指示精神，加大高质量科技供给和 政策支持，充分发挥企业创新主体作用，着力推动生物医药产业提质升级，研发生产更多优质高效的好 ...

Core Insights - The Chinese government emphasizes the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry, aiming for the development of more effective new drugs to improve public health [2][3] Group 1: Government Initiatives - The government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [2] - There is a significant market potential in the health industry, with a strong emphasis on identifying innovative drug projects with high clinical value and conversion potential [2][3] - The government encourages the cultivation of quality enterprises and provides policy support in areas such as talent and financing, while promoting international cooperation [2] Group 2: Research and Development Focus - The government stresses the importance of original innovation and tackling key core technologies, leveraging both government and market resources to foster innovation [3] - There is a call for the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [3] - The government aims to modernize and industrialize traditional Chinese medicine by applying modern scientific theories and technologies [3]

Core Changes - Shareholder Change: Baker Brothers Life Sciences, L.P. and its affiliates reduced their shareholding from 8.06% to 7.99%, a decrease of 0.07 percentage points [1] - Share Count Unchanged: The number of shares held remains at 115,666,055, indicating passive dilution [1] Reason for Change - Date: August 19, 2025 [1] - Specifics: The company's subsidiary BG NC 2, Ltd. transferred 13 million common shares to a custodian in exchange for an equivalent number of American Depositary Shares [1] - Purpose: This transfer is intended to fulfill unvested equity awards under the 2016 option and incentive plan [1] Important Notes - No Change in A-Shares: This change does not affect the number of A-shares [1] - No Trigger for Mandatory Offer: The change does not trigger any mandatory offer obligations [1] - Governance Structure Unchanged: There is no alteration in the company's governance structure [1] - No Need for Disclosure: There is no requirement to disclose an equity change report or related documents [1] - Passive Dilution: The change is classified as passive dilution due to share issuance, with no actual change in the number of shares held by the shareholder [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於持股5%以上 股東權益變動觸及1%刻度的提示性公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年8月20日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、 ...

一、 信息披露义务人及其一致行动人的基本信息 美股代码：ONC 百济神州有限公司 关于持股5%以上股东权益变动 触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 | 信息披露义务人名称 | | | | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | --- | --- | --- | | Baker | Brothers | | Life | ☐ ☐ | 控股股东/实控人 控股股东/实控人的一致 | 不适用 | | Sciences, | 及 L.P. | 其 | 联 | 行动人 | | ☑ | | 属实体 | | | | ☑ | 其他直接持股股东 | | 二、 权益变动触及 1%刻度的基本情况 百济神州有限公司（以下简称"公司"）的子公司 BG NC 2, Ltd.于 2025 年 8 月 19 日（美国东部时间）向公司的托管公司移交 13,000,000 股公司的普通股， 用以换取相应数量的美国存托股份（每股美国存托股份相当于 13 股普通股），旨 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.91% as of August 20, 2025, with mixed performance among constituent stocks [1] - Heartbeat Medical led the gains with an increase of 3.13%, while Yuandong Biological experienced the largest decline [1] - The market for the Sci-Tech Medical ETF managed by Harvest saw a turnover rate of 24.05% and a transaction volume of 62.637 million yuan, indicating active trading [3] Group 2 - The latest scale of the Sci-Tech Medical ETF reached 263 million yuan, marking a one-month high and ranking first among comparable funds [3] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.157 million yuan, totaling 15.2382 million yuan [3] - The net value of the ETF increased by 56.59% over the past year, with the highest monthly return since inception being 23.29% [3] Group 3 - The total amount of business cooperation for innovative drugs in China is projected to reach 51.9 billion USD in 2024, with a record 1.25 billion USD upfront payment transaction between 3SBio and Pfizer in 2025 [4] - The Chinese innovative drug sector has seen a 25.02% increase year-to-date, ranking fourth among 31 industries, with a current PE ratio of 31.31 times [4] - The National Healthcare Security Administration has introduced a temporary management method for disease-based payment, promoting payment reform in the healthcare sector [4] Group 4 - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading companies including United Imaging and BeiGene [4][6] - The performance of individual stocks varied, with United Imaging down by 0.26% and BeiGene up by 0.95% [6] - Investors without stock accounts can access the Sci-Tech Medical ETF through the Harvest Sci-Tech Medical ETF linked fund [6]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The company's net profit attributable to shareholders was $95.59 million, showing a significant increase of 125.73% year-over-year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licenses for five drugs and investigational drugs, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene that are already marketed in China, along with two investigational drugs in clinical stages [2] Company Background - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 [2] - As of July 2018, the company had a global team of over 1,300 employees, showcasing its comprehensive capabilities in research, clinical development, manufacturing, and commercialization [2]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - Public funds have conducted over 3,800 research visits in the past month, with more than 150 institutions participating, indicating a strong interest in stock selection [2][3] - The average stock price increase of the companies researched by public funds reached 14.96%, significantly outperforming the market, with the top ten stocks seeing increases exceeding 73% [2] - The most favored sectors by public funds are TMT (Technology, Media, and Telecommunications) and pharmaceuticals, with 63 electronic companies and 47 pharmaceutical companies being researched extensively [3] Group 2 - The focus on AI technology is seen as a revolutionary change, with ongoing demand expected to drive growth across various industries [3] - In the pharmaceutical sector, there is an expectation of increased revenue for innovative drug companies, attracting long-term investments, with 2025 projected as a pivotal year for profitability [4] - The Chinese pharmaceutical industry is undergoing a valuation reset, with expectations of extended product life cycles and increased sales peaks due to the integration of commercial strategies [4]

Group 1 - China's innovative drug assets are increasingly recognized globally, capturing a larger share of the global innovative drug licensing market, with 27% of global transaction volume and 32% of transaction value in 2023 [1] - Despite the growth, only 10 out of 307 new drugs approved by the FDA since 2019 are from China, representing less than 3% [1][11] - The market capitalization of Chinese pharmaceutical and biotech companies is significantly lower than their US counterparts, with only 14% of the total market cap of US listed companies [7] Group 2 - The Hong Kong stock market has seen multiple "10x stocks" in the pharmaceutical sector, with companies like Deqi Medicine and Hengrui Medicine experiencing significant price increases [4][5] - The recent IPOs of biopharmaceutical companies in Hong Kong have nearly matched the total for 2023, indicating a strong market interest [5] - A wave of high-profile IPOs is expected in the second half of 2025, driven by improved market conditions and increased liquidity [5][6] Group 3 - The capital market's enthusiasm has led to significant refinancing activities among listed companies, with major transactions from companies like Innovent Biologics and I-Mab [6] - Chinese companies now account for about one-third of the global pipeline of innovative drugs, with a total transaction scale of $48 billion in the first half of 2025 [6] - The trend of increasing licensing agreements with multinational pharmaceutical companies is expected to continue, as many innovative drugs are entering clinical stages [9][10] Group 4 - The focus of Chinese innovative drugs remains on oncology, with over 60% of licensing transactions in the past three years related to cancer treatments [12] - There is a rising interest in cardiovascular and metabolic disease drugs, particularly GLP-1 medications, which are becoming a focal point for multinational companies [12][13] - The global valuation of innovative drugs is undergoing a transformation, with a cautious approach towards high-priced acquisitions of late-stage drugs [10]